Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RUA Life Sciences's Other Operating Expense for the
six
months ended in Mar. 2026 was €-0.02 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.02 Mil.
RUA Life Sciences's quarterly Other Operating Expense
increased
from Sep. 2024 (€-1.30 Mil) to Mar. 2025 (€0.15 Mil) but then
declined
from Mar. 2025 (€0.15 Mil) to Mar. 2026 (€-0.02 Mil).
RUA Life Sciences's annual Other Operating Expense
increased
from Mar. 2022 (€1.76 Mil) to Mar. 2023 (€2.17 Mil) but then
declined
from Mar. 2023 (€2.17 Mil) to Mar. 2024 (€1.98 Mil).
RUA Life Sciences Other Operating Expense Related Terms
RUA Life Sciences Other Operating Expense Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €-0.02 Mil mean?
RUA Life Sciences (FRA:AOHA) has a Other Operating Expense of €-0.02 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on RUA Life Sciences and its competitors.
Is RUA Life Sciences' Other Operating Expense too high?
RUA Life Sciences' current Other Operating Expense is €-0.02 Mil. Overall, RUA Life Sciences has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' Other Operating Expense compare to ABT and SYK?
RUA Life Sciences' Other Operating Expense of €-0.02 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Devices & Instruments company?
A good Other Operating Expense depends on the Medical Devices & Instruments industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on RUA Life Sciences and its competitors. RUA Life Sciences's current Other Operating Expense is €-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (FRA:AOHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.15, compared to a current price of €0.29 — trading 92% above its estimated fair value. The current Other Operating Expense is €-0.02 Mil. RUA Life Sciences' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For RUA Life Sciences (FRA:AOHA), the current Other Operating Expense is €-0.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (FRA:AOHA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of €0.29 is trading 92% above its estimated GF Value™ of €0.15.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:AOHA:
Other Operating Expense: €-0.02 Mil
GF Value™: €0.15 vs. price of €0.29 (92% above fair value)
No single metric tells the full story. See the FRA:AOHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
46GF Score
Get the complete analysis for FRA:AOHA
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AOHA has been successfully added to your 
